The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
This program of work focuses on smoking related lung diseases including chronic bronchitis and emphysema, and lung cancer, as well as diseases affecting the blood vessels in the lungs. The work includes basic cell biology and human clinical trials.There is a high likelihood that new approaches to treating lung disease will emerge.
This Practitioner Fellowship will aim to improve outcomes in people with lung cancer. The clinical studies will focus on: 1. Using low dose CT scans to detect lung cancer at a very early stage. 2. Molecular tests to diagnose lung cancer earlier, and provide information that will be useful for deciding treatment 3. Using advanced techniques to diagnose small opacities in the lung
A-Prof Greg King is a respiratory physician researcher whose studies are to define the mechanisms by which diseases, such as asthma and COPD occur. He has developed novel tools to measure lung disease, particularly complex lung function testing and lung imaging.
Better Care Of Heart And Lung Disease For Aboriginal And Torres Strait Islander People In Rural And Remote Australia
Funder
National Health and Medical Research Council
Funding Amount
$380,583.00
Summary
Lung and heart disease are major contributors to the Aboriginal Australian and Torres Strait Islander health gap. This is even more so in remote and regional Australia. This Fellowship will generate new knowledge regarding how best to prevent, diagnose and treat heart and lung disease in this setting. Based in Alice Springs, it will bring together researchers and health care providers across northern and Central Australia and link them with our leading national research institutes.
Understanding Early Life Risk Factors For Inflammation In The Rising Predisposition For NCDs
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
In 2011 the UN General Assembly identified the rise in non-communicable diseases (NCDs) as a major global threat, and prioritized preventive strategies against diseases like obesity, diabetes, heart disease, allergy and asthma. Common risk factors for these inflammatory diseases begin early in life, the most logical time for prevention. Our international interdisciplinary network aims to improve health and prevent NCDs by early interventions that reduce inflammation over the life-course.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$585,269.00
Summary
This Fellowship will allow Professor Lloyd to continue clinical and laboratory research in two areas: firstly, in relation to prevention of transmission of hepatitis C infection, and scale up of antiviral treatments, particularly amongst prisoners. Secondly, in studies investigating the biological basis of chronic fatigue states following acute infection or cancer treatment, and also in development of effective treatment for chronic fatigue states.
Determinants Of The Outcomes From Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$532,630.00
Summary
Professor Lloyd will continue studies of the factors which lead to varied clinical outcomes from common infectious diseases. The outcomes include chronic or persistent illness, rather than prompt recovery. The factors being studied include aspects of the microbes causing the infection; and aspects of the individual suffering from infection, including genetic make-up, immune defences, and treatment responses. The infections studied include common "flu-like" illnesses, as well as hepatitis C.
Chronic myeloid leukaemia was almost always fatal before the development of imatinib a decade ago, the first tyrosine kinase inhibitor (TKI) developed to treat a human cancer. There are now more potent TKIs that are effective in cases of resistance to imatinib. The challenge now is to optimise the achievement of remissions using these drugs and convert CML into a curable condition. This will be the focus of my NHMRC Practitioner Fellowship over the next 5 years.
Trials of numerous agents to slow the progression of Parkinsons disease have provided ambiguous or negative results despite having good preliminary evidence for their efficacy. The most likely reason is that many nerve cells are already destroyed by the time of diagnosis. Thus effective therapies may be most (and possible only) effective when administered in the presymptomatic stages of disease. This proposal is directed at developing method to detect early presymptomatic Parkinsons disease.
Mechanisms, Biomarkers And New Therapies For Abdominal Aortic Aneurysm
Funder
National Health and Medical Research Council
Funding Amount
$551,370.00
Summary
Approximately 5% of men and 1% of women aged over 60 years develop artery weakening. The management of artery weakening is currently focused on radiological imaging and surgery. In this fellowship work will be performed to better understand the mechanisms involved in artery weakening, assess new ways of monitoring disease progression and evaluate new medical therapies. It is envisaged that the work will identify a number of new management stratergies for this common condition.